Oxford Technology Management

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Metacarpal is a pioneering company specializing in the development of body-powered bionic prosthetic hands, designed to enhance the lives of individuals with limb differences. The company's innovative technology features variable grips that allow users to switch between different operations, providing the ability to intuitively adjust to various object shapes. This ensures a steady grip through an integrated grip lock mechanism. Metacarpal aims to offer enhanced responsiveness and precision in control, closely resembling the natural movements familiar to users. In addition to their advancements in prosthetic technology, the company is committed to addressing the needs of underserved populations in developing regions, aspiring to make their life-changing products accessible to those in most need.

CryoLogyx is an early-stage biotechnology company focused on developing innovative cryopreservation technology that enhances the freezing, storage, and transportation of cells. By utilizing advanced cryoprotectants, CryoLogyx ensures that cells remain viable and ready for use in drug discovery, diagnostics, and cell therapy applications. The company's proprietary technology facilitates the delivery of frozen, ready-to-use cells, allowing healthcare researchers to access and utilize these vital resources in their preferred formats, thereby transforming the landscape of cell storage and transportation.

MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company specializes in creating mitochondrial-protective treatments for a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By targeting the underlying mitochondrial issues associated with these challenging diseases, MitoRx Therapeutics seeks to enable healthcare professionals to halt the progression of conditions such as dystrophy and neurodegeneration. In addition to its internal research on rare indications, the company also collaborates on broader health issues, positioning itself as a key player in the field of mitochondrial medicine.

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company specializes in creating mitochondrial-protective treatments for a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By targeting the underlying mitochondrial issues associated with these challenging diseases, MitoRx Therapeutics seeks to enable healthcare professionals to halt the progression of conditions such as dystrophy and neurodegeneration. In addition to its internal research on rare indications, the company also collaborates on broader health issues, positioning itself as a key player in the field of mitochondrial medicine.

OXcan is a startup that focuses on early detection of lung cancer using advanced machine learning and liquid biopsy technologies. The company has developed an artificial intelligence-based healthcare platform that identifies cancer by analyzing targeted blood tests. This platform detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine screening. By evaluating multidimensional liquid biopsy results, which include DNA, proteins, epigenetic markers, and patient medical histories, OXcan enables healthcare providers to achieve early cancer detection and implement curative treatment strategies.

Machine Discovery is a spin-out from the University of Oxford focused on commercializing advanced machine learning technology. The company has developed a simulation management platform that utilizes proprietary neural network technology to enhance the efficiency of compute-intensive tasks. This platform enables clients to conduct simulations with minimal data input while achieving a high level of accuracy, specifically 99.9% fidelity. By accelerating costly calculations, Machine Discovery provides valuable statistical insights that aid clients in speeding up their innovation processes, thus addressing critical demands in various sectors.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, specifically through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging method enables real-time cancer detection during surgical procedures, which can significantly reduce the chances of cancer recurrence and the need for subsequent operations. Lightpoint Medical's tools are designed to enhance the effectiveness of robotic cancer surgeries, providing healthcare professionals with critical insights that improve surgical decision-making and patient outcomes while also aiming to lower healthcare costs.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Oxwash is a provider of sustainable on-demand laundry and dry cleaning services based in Oxford, United Kingdom. Founded by Dr. Kent Grant in 2018, the company focuses on delivering clinically clean garments while maintaining a commitment to net zero carbon emissions throughout its operations. Oxwash utilizes a fleet of electric cargo bikes and electric vans to ensure a nationwide zero-emission logistics footprint, enhancing its eco-friendly approach. The company's services are designed to meet the needs of customers seeking environmentally responsible washing solutions, promoting sustainability in the laundry industry.

Curileum Discovery Ltd, a biotechnology company based in London, specializes in the development of therapeutic solutions for gastrointestinal diseases. Founded in 2013, the company aims to discover and develop novel therapeutics that address severe gastrointestinal conditions early in their progression. One of its key innovations is ULI-015, a small molecule designed to redirect the production of precancerous cells in polyps toward healthy tissue. In preclinical studies, ULI-015 has shown promising results, significantly reducing polyp numbers and promoting regression and fusion with healthy tissue. Curileum has developed an efficient method to extract ULI-015 from a plant source and is pursuing Orphan Drug Designation to facilitate clinical testing in patients with familial adenomatous polyposis. Located at St Mark’s Hospital in London, the company aims to target high-risk individuals identified through bowel screening programs and is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Atelerix Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2006. It specializes in the storage and transportation of cells and tissues at room temperature, utilizing a patented technology that encapsulates biological products in a natural hydrogel. This innovative approach allows for the safe shipment and storage of viable cells, including suspended cells, planted cells, and stem cells, without the need for cryopreservation or harmful supplements. By protecting cells from biochemical and physical damage, Atelerix enables immediate use of cells and assays upon arrival, enhancing reliability in drug discovery and cell therapy applications. The company's technology contributes to more predictable and effective outcomes in medical and research settings.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, specifically through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging method enables real-time cancer detection during surgical procedures, which can significantly reduce the chances of cancer recurrence and the need for subsequent operations. Lightpoint Medical's tools are designed to enhance the effectiveness of robotic cancer surgeries, providing healthcare professionals with critical insights that improve surgical decision-making and patient outcomes while also aiming to lower healthcare costs.

Atelerix Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2006. It specializes in the storage and transportation of cells and tissues at room temperature, utilizing a patented technology that encapsulates biological products in a natural hydrogel. This innovative approach allows for the safe shipment and storage of viable cells, including suspended cells, planted cells, and stem cells, without the need for cryopreservation or harmful supplements. By protecting cells from biochemical and physical damage, Atelerix enables immediate use of cells and assays upon arrival, enhancing reliability in drug discovery and cell therapy applications. The company's technology contributes to more predictable and effective outcomes in medical and research settings.

Molecular Warehouse Ltd. is a biotechnology company focused on the development of proteins for diagnostics and therapeutics. Incorporated in 2015 and located in Twickenham, United Kingdom, the company specializes in patient-centric biosensor technology aimed at enhancing molecular diagnostics. Its innovative approach involves creating electrochemical biosensors that can detect various biomarkers with high specificity and sensitivity. This technology enables individuals to monitor their health regularly from home, allowing for timely communication of test results with healthcare providers through smart devices.

Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing innovative therapies for inflammation and autoimmune diseases. Established in 2014, the company specializes in modifying a naturally occurring protein that plays a crucial role in immunoregulation. Ducentis targets the CD200/CD200R axis, which provides a deactivating signal to activated immune cells in both the innate and adaptive immune systems. The company's research aims to address various therapeutic needs, including transplant rejection and a range of autoimmune and inflammatory conditions affecting organs such as the lungs, liver, kidneys, eyes, bones, and cartilage.

Curileum Discovery Ltd, a biotechnology company based in London, specializes in the development of therapeutic solutions for gastrointestinal diseases. Founded in 2013, the company aims to discover and develop novel therapeutics that address severe gastrointestinal conditions early in their progression. One of its key innovations is ULI-015, a small molecule designed to redirect the production of precancerous cells in polyps toward healthy tissue. In preclinical studies, ULI-015 has shown promising results, significantly reducing polyp numbers and promoting regression and fusion with healthy tissue. Curileum has developed an efficient method to extract ULI-015 from a plant source and is pursuing Orphan Drug Designation to facilitate clinical testing in patients with familial adenomatous polyposis. Located at St Mark’s Hospital in London, the company aims to target high-risk individuals identified through bowel screening programs and is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Glide Pharmaceutical Technologies Limited, established in 2001 and based in Abingdon, UK, is a clinical-stage company specializing in the development of solid dose formulations of therapeutics and vaccines. Its core technology, the Solid Dose Injector (SDI) system, aims to enhance patient compliance by facilitating self-administration of long-term therapies without the need for needles. Glide's pipeline includes solid dose formulations of octreotide, teriparatide, anthrax, and influenza vaccines. Additionally, the company is developing a non-invasive diagnostic technology focused on prostate cancer. Formerly known as Caretek Medical, the company changed its name to Glide Pharmaceutical Technologies Limited in 2006.

OxSonics Therapeutics is a biotechnology company focused on advancing anti-cancer therapies through its innovative SonoTran platform. This proprietary technology enhances the delivery and effectiveness of anti-cancer agents by improving their distribution within solid tumors, thereby increasing treatment efficacy and potentially reducing toxicity. Unlike traditional methods that often require drug reformulation, SonoTran employs a drug-agnostic approach that allows for the co-administration of particles with anti-cancer drugs, facilitating a localized pumping effect that enhances drug penetration throughout the tumor. Developed from cutting-edge research at the University of Oxford's Institute of Biomedical Engineering, SonoTran is designed to integrate seamlessly into existing oncology clinical workflows, providing real-time visualization for healthcare professionals as they treat patients. Headquartered in Oxford, UK, OxSonics aims to transform cancer treatment by addressing the significant challenges presented by solid tumors.

Electrowinning Technologies Ltd is a manufacturer based in Bristol, United Kingdom, specializing in power electronic equipment for the metal industry. Founded in 2016, the company focuses on advancing methods for controlling large electrical currents used in metal winning operations. Its offerings include copper concentration control for electrorefining, anodes with integrated point-of-use power converters for electrowinning, and flow-optimized cells aimed at enhancing copper liberation and electrowinning processes. By implementing these technological solutions, Electrowinning Technologies enables clients to enhance both the quality and quantity of metal production while reducing energy consumption, significantly impacting the efficiency of the electrorefining and electrowinning processes, particularly for copper, which is the predominant metal refining method in Europe.

Curileum Discovery Ltd, a biotechnology company based in London, specializes in the development of therapeutic solutions for gastrointestinal diseases. Founded in 2013, the company aims to discover and develop novel therapeutics that address severe gastrointestinal conditions early in their progression. One of its key innovations is ULI-015, a small molecule designed to redirect the production of precancerous cells in polyps toward healthy tissue. In preclinical studies, ULI-015 has shown promising results, significantly reducing polyp numbers and promoting regression and fusion with healthy tissue. Curileum has developed an efficient method to extract ULI-015 from a plant source and is pursuing Orphan Drug Designation to facilitate clinical testing in patients with familial adenomatous polyposis. Located at St Mark’s Hospital in London, the company aims to target high-risk individuals identified through bowel screening programs and is currently seeking funding to advance ULI-015 towards clinical proof of concept.

Lupe Technology Limited is a consumer technology company based in Old Sodbury, United Kingdom, specializing in the development and manufacturing of cordless vacuum cleaners. Founded in 2014, the company focuses on enhancing cordless vacuuming efficiency through its innovative suction intensifier technology, which incorporates a cyclonic system and HEPA filtration. Their vacuum cleaners feature a motorized agitator with a rotating seal designed to effectively remove hair and deep-seated dirt. Additionally, Lupe Technology's products are equipped with a removable battery pack, allowing users the convenience of extended cleaning without interruption.

Active Needle Technology Ltd. is a medical device start-up based in Abingdon, United Kingdom, founded in 2016. The company focuses on developing innovative needle actuating device technology that enhances precision in ultrasound-guided interventional procedures, including regional anesthesia and cancer biopsies. Its proprietary platform utilizes a hand-held, single-use piezoelectric device that induces minute longitudinal ultrasonic vibrations to improve the accuracy of needle placement. This technology aims to transform treatment pathways in interventional radiology by providing safer and more efficient methods for clinicians and healthcare providers, ultimately benefiting patients. Active Needle's advancements represent a significant improvement over existing technologies in the field.

Molecular Warehouse Ltd. is a biotechnology company focused on the development of proteins for diagnostics and therapeutics. Incorporated in 2015 and located in Twickenham, United Kingdom, the company specializes in patient-centric biosensor technology aimed at enhancing molecular diagnostics. Its innovative approach involves creating electrochemical biosensors that can detect various biomarkers with high specificity and sensitivity. This technology enables individuals to monitor their health regularly from home, allowing for timely communication of test results with healthcare providers through smart devices.

Ducentis BioTherapeutics Limited is a pre-clinical stage company based in Witney, United Kingdom, focused on developing innovative therapies for inflammation and autoimmune diseases. Established in 2014, the company specializes in modifying a naturally occurring protein that plays a crucial role in immunoregulation. Ducentis targets the CD200/CD200R axis, which provides a deactivating signal to activated immune cells in both the innate and adaptive immune systems. The company's research aims to address various therapeutic needs, including transplant rejection and a range of autoimmune and inflammatory conditions affecting organs such as the lungs, liver, kidneys, eyes, bones, and cartilage.

Orbit Discovery Ltd. is a biotechnology company based in Oxford, United Kingdom, that specializes in peptide display technology for the identification of peptide drugs aimed at treating chronic diseases. Established in 2015, the company utilizes an innovative in vitro display platform that links randomized peptide sequences to their encoding DNA on small beads, facilitating the screening of potential peptide therapeutics. This approach allows for the discovery of peptides that can offer the specificity and efficacy of larger biologic molecules while maintaining the advantages of smaller molecules, such as reduced dosage and lower manufacturing costs. Orbit Discovery's technology enhances the drug development process by enabling high-throughput screening of peptide candidates, thus supporting both internal drug discovery initiatives and collaborative research efforts.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, specifically through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging method enables real-time cancer detection during surgical procedures, which can significantly reduce the chances of cancer recurrence and the need for subsequent operations. Lightpoint Medical's tools are designed to enhance the effectiveness of robotic cancer surgeries, providing healthcare professionals with critical insights that improve surgical decision-making and patient outcomes while also aiming to lower healthcare costs.

Sime Diagnostics Ltd is a clinical AI platform company that specializes in neonatal healthcare, offering innovative solutions to improve patient outcomes in critical care settings. Founded in 2014 and based in London, the company has developed a proprietary software that provides data-driven insights to healthcare professionals, particularly in the neonatal intensive care unit. Their flagship product, the Lung Maturity Test (LMT), predicts Respiratory Distress Syndrome (RDS) in premature infants, allowing for timely interventions that can significantly reduce morbidity and mortality rates. The platform not only aids in real-time disease detection but also curates unique datasets for biomarker discovery, which can benefit both the company and its commercial partners across various medical fields. With a commitment to preventative, personalized medicine, Sime Diagnostics aims to enhance the quality of care through its advanced AI technologies.

Sasets.com is a technology company specializing in asset management software and mobile logistics solutions tailored for the construction and civil engineering sectors. Leveraging the capabilities of Microsoft Azure, the platform enhances operational efficiency by replacing outdated paperwork with a comprehensive digital system that tracks and stores essential project-related documents, drawings, forms, manuals, and photos throughout the project lifecycle. By providing real-time data and automating health and safety processes, Sasets.com empowers clients to make informed decisions, ultimately saving time and reducing costs. The company’s focus on industry-specific applications is designed to significantly improve employee productivity and streamline organizational processes in the construction industry.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and brand loyalty. The company develops mobile phone software that utilizes global positioning systems (GPS) and geofences to deliver location-specific information. This technology allows clients to send targeted push notifications to users based on their current location, effectively engaging customers at the right moment. By collaborating with prominent brands, Message Missile has established itself as a key player in the field of mobile marketing, helping businesses leverage location data to improve their marketing strategies.

Designer Carbon Materials Ltd is a company focused on the development of advanced nanomaterials, specifically endohedral metallofullerenes, for diverse applications in energy harvesting, bio-sensing, and quantum nanoelectronics. Founded as a spin-out from the University of Oxford, it builds upon over a decade of research led by Dr. Kyriakos Porfyrakis and his team. The company specializes in synthesizing and chemically functionalizing these unique carbon structures to tailor their electronic properties for various industrial and scientific uses. By licensing a comprehensive intellectual property portfolio developed by Dr. Porfyrakis and his group, Designer Carbon Materials Ltd aims to provide innovative solutions that leverage the capabilities of carbon nanostructures.

Abgentis Limited is a biotechnology company based in Abingdon, United Kingdom, focused on the development of innovative intravenous and oral antibacterial products aimed at treating acute and chronic, life-threatening, and drug-resistant infections. Established in 2012, the company specializes in the re-engineering of previously marketed antibacterials, leveraging advanced insights into structure-activity relationships, microbiology, and pharmacology. By concentrating on antibacterial DNA supercoiling inhibitors, Abgentis aims to enhance the immune response and provide effective treatment options for patients facing serious bacterial infections.

Run3D Limited is a healthcare company that specializes in musculoskeletal assessments to address persistent injuries, particularly those related to running. Founded in 2012 and based in Witney, United Kingdom, Run3D operates clinics across several locations, including Surrey, Essex, Basingstoke, London, Oxford, and Dublin. The company employs advanced three-dimensional gait analysis technology to provide objective assessments of biomechanics, identifying the root causes of injuries and offering evidence-based rehabilitation solutions. Run3D's team of trained clinicians evaluates various factors such as gait biomechanics, muscular strength, flexibility, and alignment to develop personalized treatment plans. The company leverages a state-of-the-art motion capture system and a comprehensive biomechanical database to ensure thorough evaluations. Additionally, Run3D collaborates with leading institutions, including the Running Injury Clinic at the University of Calgary, to enhance its evidence-based approach to managing musculoskeletal injuries and improving athletic performance.

Power OLEDs Ltd is a UK-based company focused on the development and manufacturing of advanced materials for organic light-emitting diode (OLED) technology. As a leader in the OLED sector, the company specializes in creating high-performance components such as hole transporters, electron transporters, electron injectors, hosts, and emitters. These products are designed to enhance the efficiency and durability of OLED displays, which are recognized for their superior performance over traditional display technologies like LED, LCD, and plasma. Power OLEDs is committed to innovation, holding a substantial intellectual property portfolio and a robust pipeline of new materials. With a management team that possesses over 60 years of combined experience in the OLED industry, the company is well-positioned to support global manufacturers in developing energy-efficient and environmentally friendly display solutions.

Combat Medical SL, based in Ajalvir, Spain, specializes in a novel treatment for superficial bladder cancer that enhances the efficacy of standard chemotherapy through a chemo-hyperthermia delivery system. This innovative approach involves heating chemotherapy agents and circulating them within the bladder, significantly reducing the recurrence rate of cancer to less than 20%, compared to the traditional treatment, which has a recurrence rate of 78% and often necessitates multiple surgeries. By improving treatment outcomes and minimizing the need for further surgical interventions, Combat Medical's solution not only offers clinical benefits but also presents substantial cost savings. The company is planning to expand its operations into the UK market.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and brand loyalty. The company develops mobile phone software that utilizes global positioning systems (GPS) and geofences to deliver location-specific information. This technology allows clients to send targeted push notifications to users based on their current location, effectively engaging customers at the right moment. By collaborating with prominent brands, Message Missile has established itself as a key player in the field of mobile marketing, helping businesses leverage location data to improve their marketing strategies.

Metal Powders & Process is seeking to build an atomiser that will produce metal powders is high volumes, with no impurities. The hope is that this will allow more industries to begin using metal powders to craft their components. Currently, contaminants in metal powders cause weak points in components, which are negligible for most purposes, but unusable under high stress in environments such as Aerospace.

Lightpoint Medical, Ltd. is a medical device company based in Rickmansworth, United Kingdom, founded in 2012. The company specializes in developing innovative imaging technologies for cancer surgery, specifically through its Cerenkov Luminescence Imaging (CLI) technology. This breakthrough intraoperative imaging method enables real-time cancer detection during surgical procedures, which can significantly reduce the chances of cancer recurrence and the need for subsequent operations. Lightpoint Medical's tools are designed to enhance the effectiveness of robotic cancer surgeries, providing healthcare professionals with critical insights that improve surgical decision-making and patient outcomes while also aiming to lower healthcare costs.

Microvisk Technologies is a UK-based company founded in 2004, specializing in the development of advanced medical devices. The company's flagship product, CoagMax, is a point-of-care monitor designed for home patient testing of INR blood levels. Utilizing innovative micro electro mechanical sensors, CoagMax allows patients to self-test in a convenient, safe, and less painful manner. The device incorporates a novel sensor chip embedded in a disposable smart strip, ensuring accurate and efficient coagulation monitoring. Through its technology, Microvisk aims to enhance patient autonomy and improve health outcomes in the management of coagulation disorders.

Ibexis Technologies is a prominent provider of innovative sensory networking, remote data acquisition, monitoring, and control solutions tailored for various industries, including Environmental, Building and Construction, Energy, and Industrial sectors. The company’s offerings enable clients to enhance customer satisfaction, reduce operational costs, improve workplace health and safety, lower carbon footprints, and ensure regulatory compliance. Ibexis Technologies supports a range of industry-specific protocols, allowing for the remote monitoring and control of industrial equipment such as HMIs and PLCs, sensors, and supervisory systems. Their open systems approach facilitates seamless integration into existing customer environments while enhancing the capabilities of on-site systems. Users can securely access, control, and monitor these systems via laptops or smart devices, receiving timely alerts and warnings. The company’s diverse product and service portfolio includes the IM SERIES Hardware and Systems, an Enterprise Monitoring Software Suite, Managed Services, System Integration Services, and expertise in hardware and software product development.

Message Missile, founded in 2013 by Thomas Young, specializes in location-based marketing solutions that enhance customer relationships and brand loyalty. The company develops mobile phone software that utilizes global positioning systems (GPS) and geofences to deliver location-specific information. This technology allows clients to send targeted push notifications to users based on their current location, effectively engaging customers at the right moment. By collaborating with prominent brands, Message Missile has established itself as a key player in the field of mobile marketing, helping businesses leverage location data to improve their marketing strategies.

Combat Medical SL, based in Ajalvir, Spain, specializes in a novel treatment for superficial bladder cancer that enhances the efficacy of standard chemotherapy through a chemo-hyperthermia delivery system. This innovative approach involves heating chemotherapy agents and circulating them within the bladder, significantly reducing the recurrence rate of cancer to less than 20%, compared to the traditional treatment, which has a recurrence rate of 78% and often necessitates multiple surgeries. By improving treatment outcomes and minimizing the need for further surgical interventions, Combat Medical's solution not only offers clinical benefits but also presents substantial cost savings. The company is planning to expand its operations into the UK market.

BioMoti Limited is a biotechnology company focused on developing innovative cancer therapeutics. Founded in 2009 and based in London, the company aims to revolutionize cancer treatment through its proprietary Oncojans, a novel class of therapeutic microparticles. These microparticles are engineered to target and penetrate the interior of cancer cells, allowing for the controlled release of therapeutic agents directly where they are needed while minimizing damage to healthy tissues. BioMoti's approach seeks to enhance the efficacy of cancer treatments and reduce the debilitating side effects commonly associated with conventional chemotherapy. Among its key products is MOTI1001, an ovarian cancer candidate that has demonstrated promising results in early preclinical studies. The Oncojan platform is versatile, compatible with various drug classes, including small molecules and larger biologicals, positioning BioMoti at the forefront of cancer treatment innovation.

Run3D Limited is a healthcare company that specializes in musculoskeletal assessments to address persistent injuries, particularly those related to running. Founded in 2012 and based in Witney, United Kingdom, Run3D operates clinics across several locations, including Surrey, Essex, Basingstoke, London, Oxford, and Dublin. The company employs advanced three-dimensional gait analysis technology to provide objective assessments of biomechanics, identifying the root causes of injuries and offering evidence-based rehabilitation solutions. Run3D's team of trained clinicians evaluates various factors such as gait biomechanics, muscular strength, flexibility, and alignment to develop personalized treatment plans. The company leverages a state-of-the-art motion capture system and a comprehensive biomechanical database to ensure thorough evaluations. Additionally, Run3D collaborates with leading institutions, including the Running Injury Clinic at the University of Calgary, to enhance its evidence-based approach to managing musculoskeletal injuries and improving athletic performance.

Acunu Analytics is a developer of database infrastructure and analytics software that specializes in low-latency, continuous analytics for big data. The company's platform enables real-time monitoring and control in various industries, such as manufacturing, telecommunications, media, and financial services, by powering dashboards and embedded applications for infrastructure monitoring and web analytics. At the core of Acunu's offerings is the Cassandra NoSQL database, and the company is actively involved in contributing innovations back to the Cassandra community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford Universities, Acunu is headquartered in London and has an additional office in California.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Select Technology is a design and engineering company, provides software solutions for the copier and multi-function device industry. It offers PaperCut MF, a print, copy, fax, and scan management solution; KPAX Manage, a print fleet management solution for resellers; Presto, which enables users to publish existing Windows print queues to iOS device; EveryonePrint, a mobile print solution; Drivve Image, a scanning software; and selectSCAN, a scanning and capture solution for employees.

Orthogem Limited is a company based in Nottingham, United Kingdom, that specializes in the development and manufacturing of synthetic bone grafts. Founded in 2001, Orthogem utilizes its patented Tripore technology platform to produce a range of synthetic bone grafts (SBGs) designed for various clinical applications, including spinal, oral, and craniofacial surgery. Its product offerings include TriPore Granules, TriPore MPA, and TriPore Blocks, which are engineered to promote optimal bone remodeling through their osteoconductive and bioactive properties. Orthogem’s materials address multiple medical challenges, such as fractures, congenital disorders, traumatic injuries, and bone cancer, ensuring reliable resorption during procedures like lumbar spine fusion.

Microvisk Technologies is a UK-based company founded in 2004, specializing in the development of advanced medical devices. The company's flagship product, CoagMax, is a point-of-care monitor designed for home patient testing of INR blood levels. Utilizing innovative micro electro mechanical sensors, CoagMax allows patients to self-test in a convenient, safe, and less painful manner. The device incorporates a novel sensor chip embedded in a disposable smart strip, ensuring accurate and efficient coagulation monitoring. Through its technology, Microvisk aims to enhance patient autonomy and improve health outcomes in the management of coagulation disorders.

Crysalin Limited is a research and development company based in London, United Kingdom, founded in June 2007. It specializes in crysalin lattice technology, which has been developed from patented research conducted at the Oxford University Laboratory of Molecular Biophysics since 2002. The company's primary focus is on crysalins, a protein-based nanotechnology that significantly enhances protein structure determination, particularly for challenging macromolecular targets such as membrane proteins and flexible soluble proteins. By imposing order on these complex structures, crysalins enable advanced imaging techniques like X-ray and electron microscopy to accurately resolve three-dimensional molecular structures. In addition to protein structure determination, Crysalin's technology holds potential applications in biosensor development and optoelectronics, expanding its impact in the field of molecular research.

Acunu Analytics is a developer of database infrastructure and analytics software that specializes in low-latency, continuous analytics for big data. The company's platform enables real-time monitoring and control in various industries, such as manufacturing, telecommunications, media, and financial services, by powering dashboards and embedded applications for infrastructure monitoring and web analytics. At the core of Acunu's offerings is the Cassandra NoSQL database, and the company is actively involved in contributing innovations back to the Cassandra community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford Universities, Acunu is headquartered in London and has an additional office in California.

Microvisk Technologies is a UK-based company founded in 2004, specializing in the development of advanced medical devices. The company's flagship product, CoagMax, is a point-of-care monitor designed for home patient testing of INR blood levels. Utilizing innovative micro electro mechanical sensors, CoagMax allows patients to self-test in a convenient, safe, and less painful manner. The device incorporates a novel sensor chip embedded in a disposable smart strip, ensuring accurate and efficient coagulation monitoring. Through its technology, Microvisk aims to enhance patient autonomy and improve health outcomes in the management of coagulation disorders.

LabMinds Limited is a company based in Oxford, United Kingdom, with an additional office in Somerville, Massachusetts, that specializes in automating solution preparation for liquid-handling laboratories in the pharmaceutical and life sciences sectors. Founded in 2009, LabMinds offers The Revo solution preparation system, which integrates advanced artificial intelligence and robotics to streamline laboratory processes. This innovative platform addresses the challenges of manual solution preparation, significantly reducing risks and waste associated with traditional methods. By utilizing cloud-based technology, LabMinds enables remote access and provides laboratories with detailed insights into chemical interactions through data collection. The company's mission is to enhance laboratory efficiency, improve accuracy, and facilitate the timely development of meaningful therapies.

Glide Pharmaceutical Technologies Limited, established in 2001 and based in Abingdon, UK, is a clinical-stage company specializing in the development of solid dose formulations of therapeutics and vaccines. Its core technology, the Solid Dose Injector (SDI) system, aims to enhance patient compliance by facilitating self-administration of long-term therapies without the need for needles. Glide's pipeline includes solid dose formulations of octreotide, teriparatide, anthrax, and influenza vaccines. Additionally, the company is developing a non-invasive diagnostic technology focused on prostate cancer. Formerly known as Caretek Medical, the company changed its name to Glide Pharmaceutical Technologies Limited in 2006.

Base4 specializes in advancing state-of-the-art technologies for single-molecule analysis. The company is dedicated to developing innovative microdroplet-based sequencing technology that enables pathogen screening and DNA analysis. This technology generates long reads from individual DNA molecules without requiring initial amplification, providing users with the ability to understand and predict diseases more effectively. Base4's solutions aim to produce cheaper, more accurate, and meaningful sequencing data for large populations at a reduced cost.

Microvisk Technologies is a UK-based company founded in 2004, specializing in the development of advanced medical devices. The company's flagship product, CoagMax, is a point-of-care monitor designed for home patient testing of INR blood levels. Utilizing innovative micro electro mechanical sensors, CoagMax allows patients to self-test in a convenient, safe, and less painful manner. The device incorporates a novel sensor chip embedded in a disposable smart strip, ensuring accurate and efficient coagulation monitoring. Through its technology, Microvisk aims to enhance patient autonomy and improve health outcomes in the management of coagulation disorders.

Diamond Microwave Devices Ltd. specializes in the development of semiconductor devices utilizing chemical vapor deposition (CVD) diamond technology. Founded in 2006 and headquartered in Leeds, United Kingdom, the company focuses on creating devices that serve both civil and defense applications, particularly in microwave power amplifiers and transmitters. As a subsidiary of Element Six (Pty) Ltd., Diamond Microwave Devices is positioned at the forefront of innovation in high-performance microwave technology.

Acunu Analytics is a developer of database infrastructure and analytics software that specializes in low-latency, continuous analytics for big data. The company's platform enables real-time monitoring and control in various industries, such as manufacturing, telecommunications, media, and financial services, by powering dashboards and embedded applications for infrastructure monitoring and web analytics. At the core of Acunu's offerings is the Cassandra NoSQL database, and the company is actively involved in contributing innovations back to the Cassandra community. Founded in 2009 by a team of researchers and engineers from Cambridge and Oxford Universities, Acunu is headquartered in London and has an additional office in California.

Azellon Limited is a company based in London, United Kingdom, that specializes in the development and commercialization of a unique tissue repair technology utilizing mesenchymal stem cells combined with a biological scaffold. The company's primary product, Cell Bandage, is designed for the repair of avascular meniscal tears in the knee, addressing a significant issue in orthopedic treatment where surgeons often resort to partial or complete meniscus removal. This conventional approach can lead to osteoarthritic changes in the knee joint over time. Developed by Professor Anthony Hollander, Azellon's technology has demonstrated notable success in in-vitro models over a five-year research period. Established in 2007, Azellon Limited aims to offer a more effective solution for knee injuries that preserves the meniscus and promotes natural healing.

Warwick Effect Polymers Limited manufactures and markets complex polymers using living controlled radical polymerization.

OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Mirriad Advertising, established in 2015 and headquartered in London, specializes in in-video advertising solutions. It uses artificial intelligence and computer vision technology to dynamically insert products and signage into existing video content, creating new advertising inventory for content producers and distributors. This approach enhances viewer engagement and limits commercial interruptions. Mirriad serves clients in the UK, US, China, and other countries, generating the majority of its revenue in the US.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.

Meciria develops an oil well drilling tool for the oil industry.

Glide Pharmaceutical Technologies Limited, established in 2001 and based in Abingdon, UK, is a clinical-stage company specializing in the development of solid dose formulations of therapeutics and vaccines. Its core technology, the Solid Dose Injector (SDI) system, aims to enhance patient compliance by facilitating self-administration of long-term therapies without the need for needles. Glide's pipeline includes solid dose formulations of octreotide, teriparatide, anthrax, and influenza vaccines. Additionally, the company is developing a non-invasive diagnostic technology focused on prostate cancer. Formerly known as Caretek Medical, the company changed its name to Glide Pharmaceutical Technologies Limited in 2006.

Novacta Biosystems Ltd, founded in 2003, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for bacterial infections, particularly those caused by drug-resistant bacteria. Utilizing expertise from GSK's Biotransformation and Natural Products scientific team, the company has established a dual business model that encompasses both the development of a therapeutic pipeline and the provision of biocatalysis and microbial pathway engineering services. Novacta specializes in the discovery, development, and commercialization of a novel class of small peptide molecules known as lantibiotics, which are designed to combat infections such as Clostridium difficile. Through its efforts, Novacta aims to address critical needs in the field of infectious diseases by providing effective anti-infective solutions.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Pharma Engineering has developed and patented a gentle method to remove tablets and capsules from blister packs without damaging them. The pharmaceutical industry is large and manufactures billions of blister-packaged tablets. It is common for 2-6% of this manufactured product to be stopped for quality reasons relating to the packaging. Recovering these tablets so that they can be re-packaged can yield easy savings.

Oxtox is developing Drugsensorâ„¢, a device that uses novel and cost-effective technology to rapidly detect whether a person is currently 'under the influence' of specific drugs, all with a minimum of inconvenience.

Incentec Ltd has been developing a predictive diagnostic for pre-eclampsia, a poorly defined condition affecting approximately 6% of first pregnancies. The causes of pre-eclampsia are unknown, although a failure in placental development is thought to be a factor. There is no diagnostic test currently in use and at the moment, at-risk patients (or suspected cases of pre-eclampsia) are monitored and treated on the basis of observable and developing clinical symptoms.

Imagineer Systems Limited is a developer of visual effects solutions based in Guildford, United Kingdom, established in 2000. The company specializes in research, development, and marketing services for the film, video, and broadcast post-production markets. Its software offerings include monet, a comprehensive tracking and compositing toolset, and mokey, designed for the removal of wires, rigs, logos, scratches, and hair from footage. Additionally, Imagineer Systems provides mocha, a 2D tracking and rotoscoping tool that creates precise tracks for special effects, as well as virtual product placement, lens distortion correction, noise reduction, grain management, and keying tools. Through its innovative products, the company supports the visual effects needs of commercial, film, and corporate video productions.

Dexela is a company focused on developing advanced 3-D breast imaging technology aimed at the early detection of breast cancer. It offers a range of products, including the DexTop Digital Mammography Workstation, which enhances screening workflow and performance, and a 3D reconstruction engine provided to original equipment manufacturer (OEM) partners under licensing agreements. The company manufactures flat panel CMOS X-ray detectors utilized in various medical applications, such as mammography, tomosynthesis, breast CT, and dental imaging, as well as in scientific and non-destructive testing applications. In addition to its product offerings, Dexela provides consulting services related to digital tomosynthesis and optimal 3D data reconstruction. Founded in 2003 and headquartered in London, the company also maintains an X-ray research and development facility in Sudbury, Massachusetts.

Usentric develops online proxy solution for brands in the retail, financial services and telecommunication industries. The company's products and services include secure payment online solutions, email protection, and secure ID. It is based in Sutton, U.K.

Naked Objects Group provides Java-based application development platforms.

Glide Pharmaceutical Technologies Limited, established in 2001 and based in Abingdon, UK, is a clinical-stage company specializing in the development of solid dose formulations of therapeutics and vaccines. Its core technology, the Solid Dose Injector (SDI) system, aims to enhance patient compliance by facilitating self-administration of long-term therapies without the need for needles. Glide's pipeline includes solid dose formulations of octreotide, teriparatide, anthrax, and influenza vaccines. Additionally, the company is developing a non-invasive diagnostic technology focused on prostate cancer. Formerly known as Caretek Medical, the company changed its name to Glide Pharmaceutical Technologies Limited in 2006.

Inspiration Matters has developed a software and hardware system to drive high quality displays such as those used in car dealerships, estate agents and banks.

Impact Applications Ltd. is a software development company based in Wolverhampton, United Kingdom, specializing in enterprise software applications for various business sectors. The company designs, develops, and supports a range of products, including impactRESPONSE, which focuses on repairs and maintenance for social housing and insurance reinstatement; impactUNWIRED, a wireless barcode scanning solution for component distribution; impactCONNECT, a platform for bulk SMS and voice messaging; and impactCOMMERCE, an integrated e-commerce solution. In addition to its software offerings, Impact Applications provides consultancy and support services, including maintenance contracts, helpdesk assistance, and monitoring services. Established in 2000, the company has positioned itself as a versatile provider of technology solutions tailored to meet the needs of diverse industries.

Wright Fenn provides medicine pills are manufactured and packaged in blister packs. For many patients, such as those in residential or care homes, hospitals or other institutions, these pills are repackaged by the pharmacy into dosage specific monthly packs to save nursing time and reduce dosage errors. Pharmaceutical licenses typically specify the form of the packaging and so it is expensive for the manufacturers to make and package pills in bulk form for pharmacies to repackage them into dosage specific packs. During 2003, pharmacists in the UK alone deblistered and repackaged approximately 70 million packs of pills ' mostly by hand. The number of patients requiring these patient specific packs is increasing each year at about 10-15%.

Kinomi provides a better way of automatically archiving and indexing email, both by subject matter, sender and receiver groups, and by reading content, which then enables people and organisations to retrieve relevant emails much more easily, if ever they are needed at some point in the future.

BioAnaLab Ltd. is a services provider that specializes in the analysis of biologic drugs and vaccines. BioAnaLab was spun out of the University of Oxford in 2002 to meet the unique requirements of the biopharmaceutical industry. The Company helps its customers better understand the safety and efficacy of biologic drugs and vaccines by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market

Water Innovate is a developer and commercializer of advanced water and wastewater treatment technologies aimed at addressing challenges in the water and environmental sectors. By bridging the gap between research and industry innovation, the company focuses on transferring groundbreaking environmental technologies from research labs to the marketplace. Water Innovate evaluates new technologies and invests significant resources in their development, enabling a diverse range of products tailored for the international water industry. With a commitment to overcoming longstanding obstacles in the sector, Water Innovate collaborates with leading experts to bring innovative solutions to market, contributing to improved water management and environmental sustainability.

Scancell Holdings plc, established in 1997 and based in Oxford, UK, specializes in the discovery and development of novel vaccines for cancer treatment. The company's portfolio includes ImmunoBody and Moditope technology platforms, which harness the power of the immune system to target and destroy cancerous tumors. Its lead product, SCIB1, is in Phase II clinical trials for metastatic melanoma, while other candidates like SCIB2 and Modi-1 are in earlier stage trials for various solid tumors. Scancell has collaborations with BioNTech, ISA Pharmaceuticals, and academic institutions for vaccine development, including a COVID-19 vaccine project.

Warwick Effect Polymers Limited manufactures and markets complex polymers using living controlled radical polymerization.

Inscentinel uses the exquisitely sensitive olfactory sense of bees to detect minute concentrations of volatile compounds such as explosives, drugs, or odours that indicate disease. The bees are held in a harness and can then be trained to recognize particular scents, in much the same way that sniffer dogs can be trained. In the presence of the odour for which they have been trained, the bees have a proboscis extension reflex, and this is then picked up by a camera and its associated software that then sends a signal to an operator or simply logs the data. A US patent has been granted and other patent applications are proceeding.

Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.

Diamond Hard Surfaces Ltd. is a materials technology company based in Towcester, United Kingdom, that specializes in advanced amorphous diamond coatings known as Adamant. Founded in 2004, the company has developed a patented process to create these coatings at lower temperatures and in thicker layers than traditional methods. Adamant coatings are designed to improve the durability of various substrates, including steel and thermoplastics, by providing low friction, exceptional wear resistance, and enhanced load-bearing capabilities. These properties make Diamond Hard Surfaces' offerings suitable for demanding applications across multiple industries, including aerospace, defense, oil and gas, medical, motorsport, and process plants. The coatings also serve as effective barriers against chemical corrosion, making them ideal for use in harsh environments.

Novacta Biosystems Ltd, founded in 2003, is a clinical-stage biopharmaceutical company focused on developing innovative treatments for bacterial infections, particularly those caused by drug-resistant bacteria. Utilizing expertise from GSK's Biotransformation and Natural Products scientific team, the company has established a dual business model that encompasses both the development of a therapeutic pipeline and the provision of biocatalysis and microbial pathway engineering services. Novacta specializes in the discovery, development, and commercialization of a novel class of small peptide molecules known as lantibiotics, which are designed to combat infections such as Clostridium difficile. Through its efforts, Novacta aims to address critical needs in the field of infectious diseases by providing effective anti-infective solutions.

Scancell Holdings plc, established in 1997 and based in Oxford, UK, specializes in the discovery and development of novel vaccines for cancer treatment. The company's portfolio includes ImmunoBody and Moditope technology platforms, which harness the power of the immune system to target and destroy cancerous tumors. Its lead product, SCIB1, is in Phase II clinical trials for metastatic melanoma, while other candidates like SCIB2 and Modi-1 are in earlier stage trials for various solid tumors. Scancell has collaborations with BioNTech, ISA Pharmaceuticals, and academic institutions for vaccine development, including a COVID-19 vaccine project.

Hardide Coatings is a UK-based company specializing in low-temperature chemical vapor deposition coatings made from tungsten carbide. These advanced coatings are designed to enhance the durability and longevity of metal components used in harsh environments characterized by abrasion, erosion, corrosion, and chemical aggression. Hardide's proprietary technology produces nanostructured coatings that provide exceptional wear and corrosion resistance while maintaining a balance of toughness and ductility. The company's products are utilized across various high-value sectors, including oil and gas, aerospace, petrochemical, power generation, defense, and industrial tooling. Hardide operates through distinct segments in the UK and the United States, focusing on delivering innovative solutions that extend the lifespan of critical components in demanding applications.

Invro Limited is an electronic engineering company based in Bristol, United Kingdom, established in 2003. The company specializes in the efficient management of electrical energy through electronic means. Its product offerings include single earpiece radios, radio receiver sets, FM radios, and high voltage power supplies tailored for scientific and industrial applications. In addition, Invro develops instrumentation for power electronics applications and various energy technologies, including smart-metering sensing and energy management devices. By focusing on innovative energy solutions, Invro aims to support industrial and scientific enterprises in optimizing their energy usage.

Caretek Medical has developed a needle-free injection technology. The system comprises a hand-held spring-powered reusable actuator plus a single-use disposable cassette which houses a splinter of drug in solid form. In use, the cassette is engaged with the actuator and then pressed against the skin. This pressure further charges an internal spring and, at the critical point, the internal components are brought into alignment, releasing the spring which then causes the drug splinter to be pushed to a controlled and repeatable depth within the skin. The basic idea is covered by a number of patent applications which have recently started to grant.

Telegesis is a supplier of wireless mesh networking modules that leverage Silicon Labs' technology to facilitate efficient communication between devices. The company specializes in developing communication protocols designed to transmit small amounts of data over extended distances while minimizing power consumption. Its products are capable of connecting multiple devices up to one kilometer apart, automatically forming a self-configuring mesh network where data can hop from one node to another. This innovative approach enhances connectivity and reliability in various applications, making Telegesis a key player in the wireless communications industry.

Ciphergrid Ltd (previously Cipherware Ltd) has developed what it believes is a unique data access technology that, in its simplest form, enables enterprise applications (e.g. ERP, CRM, or stand alone applications such as MS Excel) to perform transactions with multiple, disparate, remote databases across the Internet in the same way (speed, functionality, security) as if the databases were local. Ciphergrid's uniqueness lies in the fact that it offers a reliably high transactional speed, that it is a 'plug & play' solution and that it offers significantly lower total cost of ownership than any alternative. Its built-in data encryption and security control mechanisms allow the use of the Internet instead of expensive, non scaleable, leased lines.

ReviveR Technologies Limited, (formerly known as PC Help Centre) is a UK based research and development company, which specialises in designing intelligent remote diagnostic tools for use within mission-critical PCs, servers and manufacturing control equipment. Today, ReviveR Technologies offer affordable diagnostic tools that provide advanced, yet simplified secure remote access, monitor and control management for mission-critical equipment 24/7/365. The essence of the technology is that a board or chip resides in a PC or server and reports back over the internet on the detailed status of the PC. If a fault develops, the fault is reported. If it cant be corrected remotely as is often possible with software faults, then an engineer is able to arrive with the necessary hardware module so that the fault may be fixed at a single visit.